Samal Monalisha, Srivastava Varsha, Khan Muzayyana, Insaf Areeba, Penumallu Naveen Reddy, Alam Aftab, Parveen Bushra, Ansari Shahid Hussain, Ahmad Sayeed
Centre of Excellence in Unani Medicine, Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Phytother Res. 2025 Jan;39(1):25-50. doi: 10.1002/ptr.8344. Epub 2024 Nov 4.
Alzheimer's disease (AD) is considered one of the most common neurological conditions associated with memory and cognitive impairment and mainly affects people aged 65 or above. Even with tremendous progress in modern neuroscience, a permanent remedy or cure for this crippling disease is still unattainable. Polyphenols are a group of naturally occurring potent compounds that can modulate the neurodegenerative processes typical of AD. The present comprehensive study has been conducted to find out the preclinical and clinical potential of polyphenols and elucidate their possible mechanisms in managing AD. Additionally, we have reviewed different clinical studies investigating polyphenols as single compounds or cotherapies, including those currently recruiting, completed, terminated, withdrawn, or suspended in AD treatment. Natural polyphenols were systematically screened and identified through electronic databases including Google Scholar, PubMed, and Scopus based on in vitro cell line studies and preclinical data demonstrating their potential for neuroprotection. A total of 63 significant polyphenols were identified. A multimechanistic pathway for polyphenol's mode of action has been proposed in the study. Out of 63, four potent polyphenols have been identified as promising potential candidates, based on their reported clinical efficacy. Polyphenols hold tremendous scope for the development of a future drug molecule as a phytopharmaceutical that may be incorporated as an adjuvant to the therapeutic regime. However, more high-quality studies with novel delivery methods and combinatorial approaches are required to overcome obstacles such as bioavailability and blood-brain barrier crossing to underscore the therapeutic potential of these compounds in AD management.
阿尔茨海默病(AD)被认为是与记忆和认知障碍相关的最常见神经疾病之一,主要影响65岁及以上的人群。尽管现代神经科学取得了巨大进展,但这种致残性疾病的永久治疗方法或治愈方法仍然无法实现。多酚是一类天然存在的强效化合物,可调节AD典型的神经退行性过程。本综合研究旨在探究多酚的临床前和临床潜力,并阐明其在管理AD中的可能机制。此外,我们还回顾了不同的临床研究,这些研究将多酚作为单一化合物或联合疗法进行研究,包括目前正在招募、已完成、已终止、已撤回或已暂停的AD治疗研究。基于体外细胞系研究和临床前数据证明其神经保护潜力,通过包括谷歌学术、PubMed和Scopus在内的电子数据库对天然多酚进行了系统筛选和鉴定。共鉴定出63种重要的多酚。该研究提出了多酚作用模式的多机制途径。在这63种多酚中,基于其已报道的临床疗效,已鉴定出四种强效多酚作为有前景的潜在候选物。多酚作为一种植物药,在未来药物分子的开发方面具有巨大潜力,可作为辅助药物纳入治疗方案。然而,需要更多采用新型给药方法和联合方法的高质量研究,以克服生物利用度和血脑屏障穿越等障碍,从而突出这些化合物在AD管理中的治疗潜力。